Ruxolitinib in Operable Head and Neck Cancer

NCT03153982 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped Low accrual

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Ruxolitinib

Sponsor

University of California, San Francisco

Collaborators

[object Object]